🔗 Share this article

The Nobel Prize in medical science was awarded for transformative findings that illuminate how the immune system attacks harmful infections while protecting the healthy tissues.

Three renowned researchers—from Japan Prof. Sakaguchi and US experts Mary Brunkow and Fred Ramsdell—share this accolade.

Their research identified unique "security guards" within the immune system that remove rogue immune cells capable of harming the organism.

The discoveries are now enabling new treatments for autoimmune diseases and malignancies.

These laureates will divide a prize fund worth 11 million SEK.

Crucial Discoveries

"Their research has been essential for comprehending how the body's defenses operates and the reason we do not all develop severe autoimmune diseases," stated the head of the Nobel Committee.

The trio's research explain a fundamental question: How does the immune system protect us from countless infections while keeping our own tissues unharmed?

Our immune system employs immune cells that scan for signs of infection, even pathogens and bacteria it has not met before.

Such defenders employ sensors—called recognition units—that are produced randomly in a vast number of variations.

That gives the defense network the ability to fight a wide array of invaders, but the randomness of the process inevitably creates white blood cells that may target the host.

Security Guards of the Body

Scientists previously knew that a portion of these problematic white blood cells were eliminated in the immune organ—the site where white blood cells mature.

This year's Nobel Prize recognizes the discovery of T-reg cells—described as the body's "security guards"—which patrol the system to neutralize any defenders that attack the healthy cells.

We know that this mechanism malfunctions in self-attack conditions such as juvenile diabetes, MS, and rheumatoid arthritis.

A prize committee added, "These discoveries have established a novel area of research and accelerated the development of innovative therapies, for instance for cancer and immune disorders."

Regarding malignancies, T-regs block the system from attacking the growth, so research are focused on lowering their numbers.

For autoimmune diseases, trials are testing boosting regulatory T-cells so the body is not under attack. A comparable approach could also be effective in minimizing the risks of organ transplant failure.

Innovative Studies

Prof Sakaguchi, of a Japanese institution, performed tests on mice that had their immune gland extracted, causing self-attack conditions.

He demonstrated that injecting defense cells from healthy mice could stop the illness—implying there was a mechanism for preventing defenders from harming the host.

Dr. Brunkow, from the a research center in Seattle, and Dr. Ramsdell, now at a biotech firm in San Francisco, were studying an genetic autoimmune disease in rodents and humans that led to the discovery of a gene vital for how regulatory T-cells operate.

"Their groundbreaking work has uncovered how the immune system is controlled by regulatory T cells, preventing it from mistakenly targeting the body's own tissues," commented a leading physiology specialist.

"The research is a striking example of how fundamental biological study can have far-reaching consequences for public health."